Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer's disease: A new approach to therapy

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 6, 2013, Pages 870-881

  Sochocka, Marta ^a   Koutsouraki, Euphrosyni S ^b   Gasiorowski, Kazimierz ^c   Leszek, Jerzy ^c  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Alzheimer's disease; Mitochondrial failure; Neurodegeneration; Neuroinflammation; ROS; Vascular dysfunction

Indexed keywords

ACETYLCHOLINE; ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; CHEMOKINE; CYTOCHROME C OXIDASE; DOCOSAHEXAENOIC ACID; DONEPEZIL; GALANTAMINE; GLYCEROPHOSPHORYLCHOLINE; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; LEVACECARNINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLSERINE; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; RIVASTIGMINE; ROSIGLITAZONE; S ADENOSYLMETHIONINE; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CALCIUM HOMEOSTASIS; CELL DEATH; CELL SURVIVAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MUTATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; TISSUE METABOLISM; UPREGULATION; VASCULAR AMYLOIDOSIS; VASCULAR DISEASE;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; CEREBROVASCULAR CIRCULATION; ENDOTHELIUM, VASCULAR; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME;

EID: 84877030960     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113129990072     Document Type: Article

References (146)

1. Khairallah, M.I.; Kassem, L.A. Alzheimer's disease: current status of etiopathogenesis and therapeutic strategies. Pak. J. Biol. Sci., 2011, 14(4), 257-272.
2. Mirra, S.S.; Heyman, A.; McKeel, D.; Sumi, S.M.; Crain, B.J.; Brownlee, L.M.; Vogel, F.S.; Hughes, J.P.; van Belle, G.; Berg, L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology, 1991, 41(4), 479-486.
3. Gendron, T.F.; Petrucelli, L. The role of tau in neurodegeneration. Mol. Neurodegener., 2009, 4, 13.
4. Lee, G. Tau Protein: An Update on Structure and Function. Cell Motil. Cytoskeleton, 1990, 15(4), 199-203.
5. Sergeant, N.; Delacourte, A.; Buée, L. Tau protein as a differential biomarker of tauopathies. Biochim. Biophys. Acta, 2005, 1739(2-3), 179-197.
6. Takashima, A. Tau aggregation is a therapeutic target for Alzheimer's disease. Curr. Alzheimer Res., 2010, 7(8), 665-669.
7. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 1991, 12(10), 383-388.
8. Morawe, T.; Hiebel, C.; Kern, A.; Behl, C. Protein Homeostasis, Aging and Alzheimer's Disease. Mol. Neurobiol., 2012, Feb 24 [Epub ahead of print].
9. Karran, E.; Mercken, M.; De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov., 2001, 10(9), 698-712.
10. de la Torre, J.C.; Mussivand, T. Can disturbed brain microcirculation cause Alzheimer's disease? Neurol. Res., 1993, 15(3), 146-153.
11. de la Torre, J.C. Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2000, 14, S72-S81.
12. Zlokovic, B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci., 2011, 12(12), 723-738.
13. Iadecola, C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol., 2010, 120(3), 287-296.
14. Viswanathan, A.; Greenberg, S.M. Cerebral amyloid angiopathy in the elderly. Ann. Neurol., 2011, 70(6), 871-880.
15. Murray, I.V.; Proza, J.F.; Sohrabji, F.; Lawler, J.M. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp. Biol. Med., 2011, 236(7), 772-782.
16. De la Torre, J.C. Cerebrovascular and cardiovascular pathology in Alzheimer's disease. Int. Rev. Neurobiol., 2009, 84, 35-48.
17. Attwell, D.; Buchan, A.M.; Charpak, S.; Lauritzen, M.; Macvicar, B.A.; Newman, E.A. Glial and neuronal control of brain blood flow. Nature, 2010, 468(7321), 232-243.
18. Quaegebeur, A.; Lange, C.; Carmeliet, P. The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron, 2011, 71(3), 406-424.
19. Liebner, S.; Czupalla; C.J.; Wolburg, H. Current concepts of bloodbrain barrier development. Int. J. Dev. Biol., 2011, 55(4-5), 467-476.
20. Coisne, C.; Engelhardt, B. Tight junctions in brain barriers during central nervous system inflammation. Antioxid. Redox Signal., 2001, 15(5), 1285-1303.
21. Zhu, X.; Smith, M.A.; Honda, K.; Aliev, G.; Moreira, P.I.; Nunomura, A.; Casadesus, G.; Harris, P.L.; Siedlak, S.L.; Perry, G. Vascular oxidative stress in Alzheimer disease. J. Neurol. Sci., 2007, 257(1-2), 240-246.
22. Kennedy, K.A.; Sandiford, S.D.; Skerjanc, I.S.; Li, S.S. Reactive oxygen species and the neuronal fate. Cell. Mol. Life Sci., 2012, 69(2), 215-221.
23. Gutowicz, M. The influence of reactive oxygen species on the central nervous system. Postepy Hig. Med. Dosw., 2001, 65, 104-113.
24. Loh, K.P.; Huang, S.H.; De Silva, R.; Tan, B.K.; Zhu, Y.Z. Oxidative stress: apoptosis in neuronal injury. Curr. Alzheimer Res., 2006, 3(4), 327-337.
25. Jomova, K.; Vondrakova, D.; Lawson, M.; Valko, M. Metals, oxidative stress and neurodegenerative disorders. Mol. Cell Biochem., 2010, 345(1-2), 91-104.
26. Bartz, R.R.; Piantadosi, C.A. Clinical review: oxygen as a signaling molecule. Crit. Care, 2010, 14, 234.
27. Jiang, F.; Zhang, Y.; Dusting, G.J. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol. Rev., 2011, 63(1), 218-242.
28. Dikalov, S. Cross talk between mitochondria and NADPH oxidases. Free Radic. Biol. Med., 2011, 51(7), 1289-1301.
29. Block, M.L. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci., 2008, 9(Suppl 2), S8.
30. Kulbacka, J.; Saczko, J.; Chwiłkowska, A. Oxidative stress in cells damage processes. Pol. Merk. Lek., 2009, 27(157), 44-47.
31. Chrissobolis, S.; Miller, A.A.; Drummond, G.R.; Kemp-Harper, B.K.; Sobey, C.G. Oxidative stress and endothelial dysfunction in cerebrovascular disease. Front. Biosci., 2011, 16, 1733-1745.
32. Ansari, M.A.; Scheff, S.W. NADPH-oxidase activation and cognition in Alzheimer disease progression. Free Radic. Biol. Med., 2011, 51(1), 171-178.
33. Choi, S.H.; Aid, S.; Kim, H.W.; Jackson, S.H.; Bosetti, F. Inhibition of NADPH oxidase promotes alternative and antiinflammatory microglial activation during neuroinflammation. J. Neurochem., 2012, 120(2), 292-301.
34. Park, L.; Anrather, J.; Zhou, P.; Frys, K.; Pitstick, R.; Younkin, S.; Carlson, G.A.; Iadecola, C. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J. Neurosci., 2005, 25(7), 1769-1777.
35. Park, L.; Wang, G.; Zhou, P.; Zhou, J.; Pitstick, R.; Previti, M.L.; Younkin, L.; Younkin, S.G.; Van Nostrand, W.E.; Cho, S.; Anrather, J.; Carlson, G.A.; Iadecola, C. Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc. Natl. Acad. Sci. USA, 2011, 108(12), 5063-5068.
36. Du, H.; Li, P.; Wang, J.; Qing, X.; Li, W. The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. Cell. Mol. Neurobiol., 2012, 32(1), 141-147.
37. Garcia-Alloza, M.; Prada, C.; Lattarulo, C.; Fine, S.; Borrelli, L.A.; Betensky, R.; Greenberg, S.M.; Frosch, M.P.; Bacskai, B.J. Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. J. Neurochem., 2009, 109(6), 1636-1647.
38. Dietrich, H.H.; Xiang, C.; Han, B.H.; Zipfel, G.J.; Holtzman, D.M. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol. Neurodegener., 2010, 5, 15.
39. Simonyi, A.; He, Y.; Sheng, W.; Sun, A.Y.; Wood, W.G.; Weisman, G.A.; Sun, G.Y. Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease. Mol. Neurobiol., 2010, 41(2-3), 73-86.
40. Akhter, H.; Katre, A.; Li, L.; Liu, X.; Liu, R.M. Therapeutic potential and anti-amyloidosis mechanisms of tertbutylhydroquinone for Alzheimer's disease. J. Alzheimers Dis., 2011, 26(4), 767-778.
41. Sun, A.Y.; Wang, Q.; Simonyi, A.; Sun, G.Y. Botanical phenolics and brain health. Neuromol. Med., 2008, 10, 259-274.
42. Albarracin, S.L.; Stab, B.; Casas, Z.; Sutachan, J.J.; Samudio, I.; Gonzalez, J.; Gonzalo, L.; Capani, F.; Morales, L.; Barreto, G.E. Effects of natural antioxidants in neurodegenerative disease. Nutr. Neurosci., 2012, 15(1), 1-9.
43. Huang, L.; Guan, T.; Qian, Y.; Huang, M.; Tang, X.; Li, Y.; Sun, H. Anti-inflammatory effects of maslinic acid, a natural triterpene, in cultured cortical astrocytes via suppression of nuclear factorkappa B. Eur. J. Pharmacol., 2011, 672(1-3), 169-174.
44. Zhao, B. Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochem. Res., 2009, 34(4), 630-638.
45. Zotova, E.; Nicoll, J.A.; Kalaria, R.; Holmes, C.; Boche, D. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res. Ther., 2010, 2(1), 1.
46. Lehnardt, S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia, 2010, 58(3), 253-263.
47. Finsen, B.; Owens, T. Innate immune responses in central nervous system inflammation. FEBS Lett., 2011, 585(23), 3806-3812.
48. Graeber, M.B.; Li, W.; Rodriguez, M.L. Role of microglia in CNS inflammation. FEBS Lett., 2011, 585(23), 3798-3805.
49. Cai, Z.; Zhao, B.; Ratka, A. Oxidative stress and β-amyloid protein in Alzheimer's disease. Neuromol. Med., 2011, 13(4), 223-250.
50. Agostinho, P.; Cunha, R.A.; Oliveira, C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr. Pharm. Des., 2010, 16(25), 2766-2778.
51. Wang, C.; Li, J.; Liu, Q. Hydrogen-rich saline reduces oxidative stress and inflammation by inhibit of JNK and NF-κB activation in a rat model of amyloid-beta-induced Alzheimer's disease. Neurosci. Lett., 2011, 491(2), 127-132.
52. Candore, G.; Bulati, M.; Caruso, C.; Castiglia, L.; Colonna-Romano, G.; Di Bona, D.; Duro, G.; Lio, D.; Matranga, D.; Pellicanò, M.; Rizzo, C.; Scapagnini, G.; Vasto, S. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenat. Res., 2010, 13(2-3), 301-313.
53. Rocha, N.P.; Teixeira, A.L.; Coelho, F.M.; Caramelli, P.; Guimarães, H.C.; Barbosa, I.G.; da Silva, T.A.; Mukhamedyarov, M.A.; Zefirov, A.L.; Rizvanov, A.A.; Kiyasov, A.P.; Vieira, L.B.; Janka, Z.; Palotás, A.; Reis, H.J. Peripheral blood mono-nuclear cells derived from Alzheimer's disease patients show elevated baseline levels of secreted cytokines but resist stimulation with κ-amyloid peptide. Mol. Cell Neurosci., 2012, 49(1), 77-84.
54. McNaull, B.B.; Todd, S.; McGuinness, B.; Passmore, A.P. Inflammation and anti-inflammatory strategies for Alzheimer's disease--a mini-review. Gerontology, 2010, 56(1), 3-14.
55. Cojocaru, I.M.; Cojocaru, M.; Miu, G.; Sapira, V. Study of interleukin-6 production in Alzheimer's disease. Rom. J. Intern. Med., 2011, 49(1), 55-58.
56. Christov, A.; Ottman, J.T.; Grammas, P. Vascular inflammatory, oxidative and protease-based processes: implications for neuronal cell death in Alzheimer's disease. Neurol. Res., 2004, 26(5), 540-546.
57. Zhao, J.; O'Connor, T., Vassar, R. The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis. J. Neuroinflamm., 2011, 8, 150.
58. Chiarini, A.; Dal Pra, I.; Whitfield, J.F.; Armato, U. The killing of neurons by beta-amyloid peptides, prions, and pro-inflammatory cytokines. Ital. J. Anat. Embryol., 2006, 111(4), 221-246.
59. Mizuno, T.; Doi, Y.; Mizoguchi, H.; Jin, S.; Noda, M.; Sonobe, Y.; Takeuchi, H.; Suzumura, A. Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity. Am. J. Pathol., 2011, 179(4), 2016-2027.
60. Chen, X.; Stern, D.; Yan, S.D. Mitochondrial dysfunction and Alzheimer's disease. Curr. Alzheimer Res., 2006, 3(5), 515-520.
61. Baloyannis, S.J.; Costa, V.; Michmizos, D. Mitochondrial alterations in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen., 2004, 19(2), 89-93.
62. Cash, A.D., Perry, G., Ogawa, O., Raina, A.K.; Raina, A.K.; Zhu, X.; Smith, M.A. Is Alzheimer's disease a mitochondrial disorder? Neuroscientist, 2002, 8(5), 489-496.
63. Zhu, X.; Raina, A.K.; Lee, H.; Casadesus, G.; Smith, M.A.; Perry, G. Oxidative stress signaling in Alzheimer's disease. Brain Res., 2004, 1000(1-2), 32-39.
64. Zhu, X.; Smith, M.A.; Perry, G.; Aliev, G. Mitochondrial failures in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen., 2004, 19(6), 345-352.
65. Devi, L.; Prabhu, B.M.; Galati, D.F.; Avadhani, N.G.; Anandatheerthavarada, H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci., 2006, 26(35), 9057-9068.
66. Moreira, P.I.; Santos, M.S.; Seica, R.; Oliveira, C.R. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J. Neurol. Sci., 2007, 257, 206-214.
67. Aliev, G.; Seyidova, D.; Neal, M.L.; Shi, J.; Lamb, B.T.; Siedlak, S.L.; Vinters, H.V.; Head, E.; Perry, G.; Lamanna, J.C.; Friedland, R.P.; Cotman, C.W. Atherosclerotic lesions and mitochondria deletions in brain microvessels as a central target for the development of human AD and like pathology in aged transgenic mice. Ann. NY Acad. Sci., 2002, 977, 45-64.
68. Moreira, P.L.; Siedlak, S.L.; Wang, X.; Santos, M.S.; Oliveira, C.R.; Tabaton, M.; Nunomura, A.; Szweda, L.I.; Aliev, G.; Smith, M.A.; Zhu, X.; Perry, G. Increased autophagic degradation of mitochondria in Alzheimer's disease. Autophagy, 2007, 3(6), 614-615.
69. Ekert, A.; Keil, U.; Marques, C.A.; Bonert, A.; Frey, C.; Schüssel, K.; Müller, WE. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem. Pharmacol., 2003, 66(8), 1627-1634.
70. Rodrigues-Santiago, B.; Casademont, J.; Nunes, V. Is mitochondrial DNA depletion involved in Alzheimer's disease? Eur. J. Hum. Genet., 2001, 9(4), 279-285.
71. Aliev, G.; Seyidova, D.; Lamb, B.T.; Obrenovich, M.E.; Siedlak, S.L.; Vinters, H.V.; Friedland, R.P.; LaManna, J.C.; Smith, M.A.; Perry, G. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurol. Res., 2003, 25(6), 665-674.
72. Moreira, P.I.; Cardoso, S.M.; Santos, M.S.; Oliveira, C.R. The key role of mitochondria in Alzheimer's disease. J. Alzheimers Dis., 2006, 9(2), 101-110.
73. Atamna, H.; Frey, W.H. 2nd. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheiemer's disease. Mitochondrion, 2007, 7(5), 297-310.
74. Jendroska, K.; Hoffmann, O.M.; Patt, S. Amyloid beta peptide and precursor protein (APP) in mild and severe brain ischemia. Ann. NY Acad. Sci., 1997, 826, 401-405.
75. Aliev, G.; Smith, M.A.; de la Torre, J.C.; Perry, G. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion, 2004, 4(5-6), 649-663.
76. Aliev, G.; Palacios, H.H.; Walrafen, B. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int. J. Biochem. Cell Biol., 2009, 41(10), 1989-2004.
77. Caroli, A.; Testa, C.; Geroldi, C.; Nobili, F.; Barnden, L.R.; Guerra, U.P.; Bonetti, M.; Frisoni, G.B. Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment. J. Neurol., 2007, 254(12), 1698-1707.
78. Bezprozvanny, I.; Mattson, M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci., 2008, 31(9), 454-463.
79. Bezprozvanny, I. Calcium signaling and neurodegenerative diseases. Trends Mol. Med., 2009, 15(3), 89-100.
80. Hengartner, M.O. The biochemistry of apoptosis. Nature, 2000, 407(6805), 770-776.
81. Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S.M.; Ahmad, M.; Alnemri, E.S.; Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 1997, 91(4), 479-489.
82. Bossy-Wetzel, E.; Newmeyer, D.D.; Green, D.R. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVDspecific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J., 1998, 17(1), 37-49.
83. Granville, D.J.; Carthy, C.M.; Jiang, H.; Shore, G.C.; McManus, B.M.; Hunt, D.W. Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett., 1998, 437(2), 5-10.
84. Andreyev, A.Y.; Kushnareva, Y.E.; Starkov, A.A. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc.), 2005, 70(2), 200-214.
85. Knight, J.A. Reactive oxygen species and the neurodegenerative disorders. Ann. Clin. Lab. Sci., 1997, 27(1), 11-25.
86. Melov, S., Adlard, P.A.; Morten, K.; Johnson, F.; Golden, T.R.; Hinerfeld, D.; Schilling, B.; Mavros, C.; Masters, C.L.; Volitakis, I.; Li, Q.X.; Laughton, K.; Hubbard, A.; Cherny, R.A.; Gibson, B.; Bush, A.I. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One, 2007, 2, e536.
87. Arispe, N.; Pollard, H.B.; Rojas, E. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc. Natl. Acad. Sci. USA, 1993, 90(22), 10573-10577.
88. Lee, G.; Pollard, H.B.; Arispe, N. Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-beta-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides, 2002, 23(7), 1249-1263.
89. Kuchibhotla, K.V.; Goldman, S.T.; Lattarulo, C.R.; Wu, H.Y.; Hyman, B.T.; Bacskai, B.J. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron, 2008, 59(2), 214-225.
90. De Felice, F.G.; Velasco, P.T.; Lambert, M.P.; Viola, K.; Fernandez, S.J.; Ferreira, S.T.; Klein, W.L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem., 2007, 282(15), 11590-11601.
91. Hsieh, H.; Boehm, J.; Sato, C.; Iwatsubo, T.; Tomita, T.; Sisodia, S.; Malinow, R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron, 2006, 52(5), 831-843.
92. Nimmrich, V.; Grimm, C.; Draguhn, A.; Barghorn, S.; Lehmann, A.; Schoemaker, H.; Hillen, H.; Gross, G.; Ebert, U.; Bruehl, C. Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J. Neurosci., 2008, 28(4), 788-797.
93. Cheung, W.D.; Hart, G.W. AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J. Biol. Chem., 2008, 283(19), 13009-13020.
94. Rybalchenko, V.; Hwang, S.Y.; Rybalchenko, N.; Koulen, P. The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Int. J. Biochem. Cell Biol., 2008, 40(1), 84-97.
95. McKee, A.C.; Kosik, K.S.; Kennedy, M.B.; Kowall, N.W. Hippocampal neurons predisposed to neurofibrillary tangle formation are enriched in type II calcium/calmodulin-dependent protein kinase. J. Neuropathol. Exp. Neurol., 1990, 49(1), 49-63.
96. Moreira, P.I.; Santos, M.S.; Moreno, A.; Oliveira, C. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci. Rep., 2001, 21(6), 789-800.
97. Pereira, C.; Santos, M.S.; Oliveira, C. Mitochondrial function impairment induced by amyloid beta-peptide on PC12 cells. Neuroreport, 1998, 9(8), 1749-1755.
98. Fossati, S.; Cam, J.; Meyerson, J.; Mezhericher, E.; Romero, I.A.; Couraud, P.O.; Weksler, B.B.; Ghiso, J.; Rostagno, A. Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-beta variants in cells composing the cerebral vessel walls. FASEB J., 2010, 24(1), 229-241.
99. Calkins, M.J.; Reddy, P.H. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochim. Biophys. Acta, 2011, 1812(4), 507-513.
100. Du, H.; Guo, L.; Yan, S.; Sosunov, A.A.; McKhann, G.M.; Yan, S.S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc. Natl. Acad. Sci. USA, 2010, 107(43), 18670-18675.
101. Mattson, M.P. Pathways towards and away from Alzheimer's disease. Nature, 2004, 430(7000), 631-639.
102. Celsi, F.; Svedberg, M.; Unger, C.; Cotman, C.W.; Carrì, M.T.; Ottersen, O.P.; Nordberg, A.; Torp, R. Beta-amyloid causes downregulation of calcineurin in neurons through induction of oxidative stress. Neurobiol. Dis., 2007, 26(2), 342-352.
103. Lacor, P.N.; Buniel, M.C.; Furlow, P.W.; Clemente, A.S.; Velasco, P.T.; Wood, M.; Viola, K.L.; Klein, W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci., 2007, 27(4), 796-807.
104. Hidalgo, C. Cross talk between Ca2+ and redox signalling cascades in muscle and neurons through the combined activation of ryanodine receptors/Ca2+ release channels. Philos. Trans. R. Soc. Lond. Biol. Sci., 2005, 360(1464), 2237-2246.
105. Lipton, S.A.; Choi, Y.B.; Takahashi, H.; Zhang, D.; Li, W.; Godzik, A.; Bankston, L.A. Cysteine regulation of protein function--as exemplified by NMDA-receptor modulation. Trends Neurosci., 2002, 25(9), 474-480.
106. David, D.C.; Hauptmann, S.; Scherping, I.; Schuessel, K.; Keil, U.; Rizzu, P.; Ravid, R.; Dröse, S.; Brandt, U.; Müller, W.E.; Eckert, A.; Götz, J. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem., 2005, 280(25), 23802-23814.
107. Quintanilla, R.A.; Matthews-Roberson, T.A.; Dolan, P.J.; Johnson, G.V. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J. Biol. Chem., 2009, 284(28), 18754-18766.
108. Thies, E.; Mandelkow, E.M. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J. Neurosci., 2007, 27(11), 2896-2907.
109. Atlante, A.; Amadoro, G.; Bobba, A.; de Bari, L.; Corsetti, V.; Pappalardo, G.; Marra, E.; Calissano, P.; Passarella, S. A peptide containing residues 26-44 of tau protein impairs mitochondrial oxidative phosphorylation acting at the level of the adenine nucleotide translocator. Biochim. Biophys. Acta, 2008, 1777(10), 1289-1300.
110. Amadoro, G.; Corsetti, V.; Stringaro, A.; Colone, M.; D'Aguanno, S.; Meli, G.; Ciotti, M.; Sancesario, G.; Cattaneo, A.; Bussani, R.; Mercanti, D.; Calissano, P. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration. J. Alzheimers Dis., 2010, 21(2), 445-470.
111. Kang, D.E.; Roh, S.E.; Woo, J.A.; Liu, T.; Bu, J.H.; Jung, A.R.; Lim, Y. The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders. Exp. Neurobiol., 2011, 20(2), 67-80.
112. Di Filippo, M.; Chiasserini, D.; Tozzi, A.; Picconi, B.; Calabresi, P. Mitochondria and the link between neuroinflammation and neurodegeneration. J. Alzheimers Dis., 2010, 20(Suppl 2), S369-379.
113. Ray, B.; Lahiri, D.K. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Curr. Opin. Pharmacol., 2009, 9(4), 434-444.
114. Mayeux, R. Clinical practice. Early Alzheimer's disease. N. Engl. J. Med., 2010, 362(23), 2194-2201.
115. Gorelick, P.B. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann. NY Acad. Sci., 2010, 1207, 155-162.
116. Levy, O.; Malagelada, C.; Greene, L. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis, 2009, 14(4), 478-500.
117. Lemere, C.A.; Masliah, E. Can Alzheimer disease be prevented by amyloidbeta immunotherapy? Nat. Rev. Neurol., 2010, 6(6), 108-119.
118. Hock, C.; Konietzko, U.; Streffer, J.R.; Tracy, J.; Signorell, A.; Müller-Tillmanns, B.; Lemke, U.; Henke, K.; Moritz, E.; Garcia, E.; Wollmer, M.A.; Umbricht, D.; de Quervain, D.J.; Hofmann, M.; Maddalena, A.; Papassotiropoulos, A.; Nitsch, R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 2003, 38(4), 547-554.
119. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet, 2008, 372(9634), 216-223.
120. Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; Trinchese, F.; Liu, S.; Gunn-Moore, F.; Lue, L.F.; Walker, D.G.; Kuppusamy, P.; Zewier, Z.L.; Arancio, O.; Stern, D.; Yan, S.S.; Wu, H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science, 2004, 304(5669), 448-452.
121. Yao, J.; Du, H.; Yan, S.; Fang, F.; Wang, C.; Lue, L.F.; Guo, L.; Chen, D.; Stern, D.M.; Gunn Moore, F.J.; Xi Chen, J.; Arancio, O.; Yan, S.S. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J. Neurosci., 2011, 31(6), 2313-2320.
122. Gibson, G.E.; Shi, Q. A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. J. Alzheimers Dis., 2010, 20, S591-S607.
123. Yao, J.; Irwin, R.W.; Zhao, L.; Nilsen, J.; Hamilton, R.T.; Brinton, R.D. Mitochondrial bioenergetics deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Nat. Acad. Sci. USA, 2009, 106(34), 14670-14675.
124. Moreira, P.I.; Cardoso, S.M.; Pereira, C.M.; Santos, M.S.; Oliveira, C.R. Mitochondria as a therapeutic target in Alzheimer's disease and diabetes. CNS Neurol. Disord. Drug Targets, 2009, 8(6), 492-511.
125. Suchy, J.; Chan, A.; Shea, T.B. Dietary supplementation with a combination of alpha-lipoid acid acetyl-L-carnitine, glycerophosphocholine, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance. Nutr. Res., 2009, 29(1), 70-74.
126. Palacios, H.H.; Yendluri, B.B.; Parvathanemi, K.; Shadlinski, V.B.; Obrenovich, M.E.; Leszek, J.; Gokhman, D.; Ga{ogonek}siorowski, K.; Bragin, V.; Aliev, G. Mitochondrion-specific antioxidants as drug treatments for Alzheimer Disease. CNS Neurol. Disord. Drug Targets, 2011, 10(2), 149-162.
127. Aliev, G.; Liu, J.; Shenk, J.C.; Fischbach, K.; Pacheco, G.J.; Chen, S.G.; Obrenovich, M.E.; Ward, W.F.; Richardson, A.G.; Smith, M.A.; Gasimov, E.; Perry, G.; Ames, B.N. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoid acid to aged rats. J. Cell Mol. Med., 2009, 13(2), 320-333.
128. Chan, A.; Shea, T.B. Effects of dietary supplementation with Nacetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing ApoE4. Neuromol. Med., 2007, 9(3), 64-69.
129. Rodriguez, M.C.; MacDonald, J.R.; Mahoney, D.J.; Parise, G.; Beal, M.F.; Tarnopolsky, M.A. Beneficial effects of creatine, CoQ10, and lipoid acid in mitochondrial disorders Muscle Nerve, 2007, 35(2), 235-242.
130. Moreira, P.I.; Harris, P.L.; Zhu, X.; Santos, M.S.; Oliveira, C.R.; Smith, M.A.; Perry, G. Lipoid acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer's disease patient fibroblasts. J. Alzheimers Dis., 2007, 12(2), 195-206.
131. Murphy, M.P.; Smith, R.A. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv. Drug Deliv. Rev., 2000, 41(2), 235-250.
132. Smith, R.A.; Porteous, C.M.; Gane, A.M.; Murphy, M.P. Delivery of bioactive molecules to mitochondria in vivo. Proc. Nat. Acad. Sci. USA, 2003, 100(9), 5407-5412.
133. Jauslin, M.L.; Meier, T.; Smith, R.A.; Murphy, M.P. Mitochondriatargeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J., 2003, 1713, 1972-1974.
134. Szeto, H.H. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J., 2006, 8(3), E521-E531.
135. Zhao, K.; Zhao, G.M.; Wu, D.; Soong, Y.; Birk, A.V.; Schiller, P.W.; Szeto, H.H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J. Biol. Chem., 2004, 279(33), 34682-34690.
136. Dumont, M.; Lin, M.T.; Beal, M.F. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J. Alzheimers Dis., 2010, 20, S633-S643.
137. Dumont, M.; Wille, E.; Calingasan, N.Y.; Tampellini, D.; Williams, C.; Gouras, G.K.; Liby, K.; Sporn, M.; Nathan, C.; Flint Beal, M.; Lin, M.T. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. J. Neurochem., 2009, 109(2), 502-512.
138. Qin, W.; Haroutunian, V.; Katsel, P.; Cardozo, C.P.; Ho, L.; Buxbaum, J.D.; Pasinetti, G.M. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch. Neurol., 2009, 66(3), 352-361.
139. Landreth, G.; Jiang, Q.; Mandrekar, S.; Haneka, M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics, 2008, 5(3), 481-489.
140. Nicolakakis, N.; Aboulkassim, T.; Ongali, B.; Lecrux, C.; Fernandes, P.; Rosa-Neto, P.; Tong, X.K.; Hamel, E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci., 2008, 28(37), 9287-9296.
141. Strum, J.C.; Shehee, R.; Virley, D.; Richardson, J.; Mattie, M.; Selley, P.; Ghosh, S.; Nock, C.; Saunders, A.; Roses, A. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers Dis., 2007, 11(1), 45-51.
142. Escribano, L.; Simón, A.M.; Perez-Mediavilla, A.; Salazar-Colocho, P.; Del Río, J.; Frechilla, D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor downregulation in an Alzheimer's disease mouse model. Biochem. Biophys. Res. Commun., 2009, 379(2) 406-410.
143. Hanyu, H.; Sato, T.; Kiuchi, A.; Sakurai, H.; Iwamoto, T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J. Am. Geriatr. Soc., 2009, 57(1), 177-179.
144. Sato, T.; Hanyu, H.; Hirao, K.; Kanetaka, H.; Sakurai, H.; Iwamoto, T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging, 2011, 32(9), 1626-1633.
145. Watson, G.S.; Cholerton, B.A.; Reger, M.A.; Baker, L.D.; Plymate, S.R.; Asthana, S.; Fishel, M.A.; Kulstad, J.J.; Green, P.S.; Cook, D.G.; Kahn, S.E.; Keeling, M.L.; Craft, S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry, 2005, 13(11), 950-958.
146. Risner, M.E.; Saunders, A.M.; Altman, J.F.; Ormandy, G.C.; Craft, S.; Foley, I.M.; Zvartau-Hind, M.E.; Hosford, D.A.; Roses, AD; Rosiglitazone in Alzheimer's Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-tomoderate Alzheimer's disease. Pharmacogenomics J., 2006, 6(4), 246-254.